Clinical Trials
4 trialsNCT06101134 2026-04-09
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
Bristol-Myers Squibb
Phase 2 Active not recruiting
NCT05415215 2026-02-10
ProHer
Hoffmann-La Roche
Phase 3 Completed
NCT05883956 2025-03-20
PREFER-HMA
Otsuka Australia Pharmaceutical Pty Ltd
Phase 3 Active not recruiting
NCT01064310 2017-04-17
PISCES
Novartis
Phase 3 Completed